Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma

To the Editor: Raje et al. (May 2 issue) 1 describe the safety profile and antitumor activity of the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 in multiple myeloma. Although bb2121 had marked activity, bridging therapy was administered to 42% of the p...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 381; no. 3; pp. e6 - 1737
Main Authors Quintás-Cardama, Alfonso, Raje, Noopur, Hege, Kristen, Kochenderfer, James N
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 18.07.2019
Subjects
Antigens
Antitumor activity
Cell Line, Tumor
Chimeric antigen receptors
Humans
Immunotherapy, Adoptive
Lymphocytes B
Lymphocytes T
Multiple Myeloma
Patients
T-Lymphocytes
Online AccessGet full text

Cover

More Information
Summary:To the Editor: Raje et al. (May 2 issue) 1 describe the safety profile and antitumor activity of the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 in multiple myeloma. Although bb2121 had marked activity, bridging therapy was administered to 42% of the patients. It would have been important to report the status of the response to bridging therapy before bb2121 infusion, since bridging therapy might have contributed substantially to the clinical efficacy observed in that subset of patients. With regard to the percentage of patients who had a response to treatment, no significant difference was observed between . . .
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc1907520